PBAC's latest decision on Progesterone: Recommended with restriction (2024). Considered for Luteal phase support as part of an assisted reproductive technology (ART) treatment cycle for infertile women.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
8
first 2014
Submissions
8
2014 → 2024
Eligible population
Infertile women undergoing assisted reproductive technology (ART) treatment cycles requiring luteal phase support, from embryo transfer until implantation confirmed by positive B-hCG measurement.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
progesterone capsule 200 mg three times daily
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Submission history
Mar 2014: Recommended · Restricted
Mar 2016: Not recommended · Restricted
Jul 2016: Recommended with restriction · Restricted
Nov 2020: Recommended with restriction · Restricted
Nov 2020: Recommended with restriction · Authority Required
Nov 2021: Recommended · Restricted
Jul 2022: Recommended with restriction · Authority Required
Jul 2024: Recommended with restriction · Authority Required